Solara Active Pharma Sciences Limited has informed the exchange regarding the approval and adoption of Board Evaluation policy and amendment to Whistle Blower Policy.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Solara Active Pharma Sciences has informed exchanges that its Board of Directors, in a meeting held on May 15, 2026, adopted a Board Evaluation Policy in compliance with SEBI Listing Regulations. The company also amended its existing Whistle Blower Policy to incorporate necessary revisions in line with applicable requirements. Both policies are now available on the company's website. This filing is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
This is a routine regulatory compliance announcement related to corporate governance policies. The adoption of Board Evaluation Policy and amendment to Whistle Blower Policy are standard requirements for listed companies. There is no direct financial or operational impact on the company or its shareholders from this announcement.